Process for the modulation of the antagonistic activity of a monoclonal antibody
Abstract
The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target molecule, or a divalent functional fragment or derivative thereof, the antibody being capable of inhibiting one or more of the biological activities of the target molecule, wherein the process comprises a stage of reconfiguration of the hinge region consisting of a modification of the amino acid sequence of the hinge region by the deletion, the addition or the substitution of at least one amino acid. The disclosure also relates to polypeptides useful for such a modulation method and the obtained antibodies.
Claims
exact text as granted — not AI-modified1 .- 25 . (canceled)
26 . An isolated monoclonal antibody comprising an amino acid sequence selected from
SEQ ID No. 2
(PKSCGCKPCICT),
SEQ ID NO. 3
(PKSCGCKPCICP),
SEQ ID No. 4
(PRDCGCKPCPPCP),
SEQ ID NO. 5
(PRDCGCHTCPPCP),
SEQ ID No. 6
(PKSCDCHCPPCP),
SEQ ID No. 22
(CKSCDKTHTCPPCP),
SEQ ID NO. 23
(PCSCDKTHTCPPCP),
SEQ ID No. 24
(PKCCDKTHTCPPCP),
SEQ ID NO. 25
(PKSCCKTHTCPPCP),
SEQ ID No. 26
(PKSCDCTHTCPPCP),
SEQ ID No. 28
(PKSCDKTCTCPPCP),
SEQ ID NO. 29
(PKSCDKTHCCPPCP),
SEQ ID NO. 33
(PSCDKTHTCPPCP),
SEQ ID NO. 35
(PKSCDKTHCPPCP),
SEQ ID No. 36
(KCDKTHTCPPCP),
SEQ ID NO. 37
(PSCKTHTCPPCP),
SEQ ID No. 38
(PKSCDTHCPPCP),
SEQ ID NO. 39
(PKSCTHTCPPCP),
SEQ ID NO. 41
(PKSCDKTHCPPC),
SEQ ID No. 42
(PKSCDCHTCPPCP),
SEQ ID NO. 43
(PKSCDCTHCPPCP),
SEQ ID No. 44
(PCSCKHTCPPCP),
SEQ ID NO. 45
(PSCCTHTCPPCP),
SEQ ID No. 46
(PSCDKHCCPPCP),
SEQ ID NO. 47
(PKSTHTCPPCP),
SEQ ID No. 48
(PKSCTCPPCP),
and
SEQ ID No. 49
(PKSCDKCVECPPCP);
or a divalent fragment of, or a derivative of, said antibody.
27 . The isolated monoclonal antibody according to claim 26 , wherein said antibody is a human antibody.
28 . The isolated monoclonal antibody according to claim 26 , wherein said antibody is an IgG1 antibody.
29 . An isolated nucleic acid encoding for a monoclonal antibody according to claim 26 .
30 .- 31 . (canceled)Join the waitlist — get patent alerts
Track US2015239958A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.